Due to the success of the 2021 inaugural scholarship, the DVM student scholarship program will return and increase its award to $75,000.
Mike Strobel, MS, DVM, president and CEO of Aurora Pharmaceutical, has announced the return of its DVM student scholarship program, which will award an increased total of $75,000 to selected third-year veterinary students pursuing a veterinary medicine degree.
According to a company release, this program strives to support the next generation of DVM professionals and lessen their financial burden.
“When we developed this program last year, one of our goals was to help alleviate the costs associated with pursuing a degree,” said Matt Klotz, DVM, equine technical service veterinarian at Aurora Pharmaceutical.
“The burden of obtaining a degree in veterinary medicine can be daunting, and we are proud to play a part in helping students overcome that when pursuing their degree,” he added.
The program launched on January 17, 2022, with an application deadline of March 18, 2022. It will offer 16 individual scholarships of $2,500; 5 individual scholarships of $5,000; and 1 individual scholarship of $10,000.
“After receiving more than 80 applications in the first year, it reinforced the need that is out there,” said Grant Weaver, DVM, swine technical service veterinarian at Aurora Pharmaceutical. “I am thrilled that Aurora has decided to continue this scholarship to support future leaders within the veterinary industry.”
According to the release, qualified applicants must be a current third-year student pursuing their degree in veterinary medicine at an accredited school within the US. Recipients will be chosen based on academic achievement, related work experience, community and university involvement, goals, essay, and letters of reference. Each application will be scored by a committee of Aurora team members.
To obtain the scholarship application, contact scholarships@aurorapharmaceutical.com.
Reference
Aurora Pharmaceutical announces second year of DVM student scholarship program. News release. Aurora Pharmaceutical. January 14, 2022. Accessed January 20, 2022.